Related Experiment Videos
Hypofibrinolysis and insulin-resistance
1Laboratoire d'Hématologie, CHU Timone, Marseille, France.
Diabete & Metabolisme
|May 1, 1991
Summary
A defect in the fibrinolytic system, marked by elevated plasminogen activator inhibitor-1 (PAI-1), is linked to cardiovascular disease risk. The relationship between insulin resistance, insulin, and PAI-1 remains unclear.
Area of Science:
- Biochemistry
- Endocrinology
- Cardiovascular Medicine
Background:
- A dysfunctional fibrinolytic system is a cardiovascular disease risk factor.
- Elevated plasminogen activator inhibitor-1 (PAI-1) plasma levels characterize this defect.
- PAI-1 is often high in insulin resistance, seen in obese and diabetic individuals.
Purpose of the Study:
- To investigate the relationship between insulin resistance, insulin levels, and PAI-1.
- To understand the mechanisms linking these factors in humans.
Main Methods:
- Cross-sectional and intervention studies were used.
- In vitro studies examined insulin's effect on PAI-1 synthesis in hepatocytes and endothelial cells.
- In vivo studies assessed acute changes in insulin levels and their impact on PAI-1.
Main Results:
- PAI-1 levels correlate closely with insulin levels in both cross-sectional and intervention studies.
- In vitro, insulin stimulates PAI-1 synthesis in hepatocytes but not endothelial cells.
- Acute in vivo insulin elevation in humans did not increase PAI-1 levels.
Conclusions:
- The precise mechanisms connecting insulin resistance, insulin, and PAI-1 in humans are not yet understood.
- Further research is needed to elucidate these complex interactions and their clinical implications for cardiovascular health.